Detalhe da pesquisa
1.
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Lancet
; 399(10321): 237-248, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953526
2.
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.
Front Immunol
; 15: 1369436, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38629062
3.
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
PLoS One
; 18(3): e0278878, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888640